Please login to the form below

Nasal polyps

This page shows the latest Nasal polyps news and features for those working in and with pharma, biotech and healthcare.

Sanofi narrows focus, shedding diabetes and cardiovascular research

The drug was first launched for atopic dermatitis in 2016, and has since scored label extensions including adolescent AD patients, asthma and chronic rhinosinusitis with nasal polyps.

Latest news

Dupixent gains can’t keep Sanofi on a growth track

First launched for atopic dermatitis in 2016, label extensions to include adolescent AD patients as well as asthma and chronic rhinosinusitis with nasal polyps helped sales of Regeneron-partnered Dupixent (dupilumab)
Sanofi/Regeneron wins another EU approval for Dupixent

This included a 57% and 51% improvement in nasal congestion/obstruction severity, compared to 19% and 15% in the placebo groups in SINUS-24 and SINUS-52. ... It also demonstrated a 33% and 27% reduction in participant’s nasal polyps score compared to a
FDA clears Dupixent as first-ever drug for chronic rhinosinusitis with nasal polyps

Nasal polyps can lead to loss of smell and often patients require surgery to remove the polyps,” said the agency’s head of pulmonary, allergy and rheumatology products Sally Seymour. ... Trials of the drug in nasal polyps have showed that it could
Sanofi's Dupixent gains asthma approval in Europe

The companies have big plans for the drug, researching its clinical benefit in other diseases driven by allergic and other type 2 inflammation, including chronic rhinosinusitis with nasal polyps. ... A phase 3 showed that Dupixent significantly improved
Dupixent helps put Sanofi back on growth track

Meanwhile, Sanofi and development partner Regeneron have also just reported new data in patients with rhinosinusitis and nasal polyps which could expand its use further.

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest Intelligence

Exploring the potential of eosinophils

Having too many eosinophils in certain tissues is an important contributor to a range of conditions including severe eosinophilic asthma (SEA), nasal polyps, eosinophilic oesophagitis and rarer, systemic diseases such as ... surgery but whose nasal

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Account Management: Competitive Salary Offered

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Senior Content Editor - Biotechnology: Salary TBC

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Principal Medical Writer: Varies on experience

PMHub

Add my company

Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Virtual congresses: video thrilled the cardio tsar: Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?: The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.: Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....